Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily inhaled corticosteroid (ICS)/long-acting beta(2) agonist (LABA) combination. FF/VI, 92/22mcg and 184/22mcg, are approved in Europe as maintenance therapy in persistent asthma. We report data from mixed treatment comparisons (MTC) o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asthma Res Pract
Hauptverfasser: Svedsater, Henrik, Stynes, Gillian, Wex, Jaro, Frith, Lucy, Leather, David, Castelnuovo, Emanuela, Detry, Michelle, Berry, Scott
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142397/
https://ncbi.nlm.nih.gov/pubmed/27965772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40733-015-0016-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge